Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...

Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...

The CRISPR company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

According to Benzinga Pro, Intellia Therapeutics's peer group average for short interest as a percentage of float is 14.00%, which means the company has more short interest than most of its peers. Did ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Evercore ISI lowered the firm’s price target on Intellia Therapeutics (NTLA) to $48 from $60 and keeps an Outperform rating on the shares after ...

Despite the market's response to the reorganization and workforce reduction, Intellia ended the fourth quarter of 2024 with a strong cash position of approximately $862 million. This financial ...

Intellia (NTLA) said it plans to focus on developing NTLA-2002 and nex-z and discontinue development of NTLA-3001, which will result in the company cutting 27% of its workforce.